The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells

Yue Zou, Mohammad M. Uddin, Sveta Padmanabhan, Yan Zhu, Pengli Bu, Ales Vancura, and Ivana Vancurova

From the Department of Biological Sciences, St. John’s University, New York, New York 11439

Edited by Luke O’Neill

The proto-oncogene Bcl3 induces survival and proliferation in cancer cells; however, its function and regulation in ovarian cancer (OC) remain unknown. Here, we show that Bcl3 expression is increased in human OC tissues. Surprisingly, however, we found that in addition to promoting survival, proliferation, and migration of OC cells, Bcl3 promotes both constitutive and interferon-γ (IFN)-induced expression of the immune checkpoint molecule PD-L1. The Bcl3 expression in OC cells is further increased by IFN, resulting in increased PD-L1 transcription. The mechanism consists of an IFN-induced, Bcl3- and p300-dependent PD-L1 promoter occupancy by Lys-314/315 acetylated p65 NF-κB. Blocking PD-L1 by neutralizing antibody reduces proliferation of OC cells overexpressing Bcl3, suggesting that the pro-proliferative effect of Bcl3 in OC cells is partly mediated by PD-L1. Together, this work identifies PD-L1 as a novel target of Bcl3, and links Bcl3 to IFNγ signaling and PD-L1-mediated immune escape.

This work was supported by National Institutes of Health Grant CA202775 (to I.V.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

1 To whom correspondence should be addressed: Dept. of Biological Sciences, St. John’s University, 8000 Utopia Parkway, New York, NY 11439. Tel.: 718-990-6409; E-mail: vancuroi@stjohns.edu.

2 The abbreviations used are: OC, ovarian cancer; EOC, epithelial ovarian cancer; WCE, whole cell extract; PD-L1, programmed death ligand 1; IFN, interferon-γ; IL, interleukin; TNF, tumor necrosis factor; TSS, transcription start site; Lys-314/315 ac-p65, Lys-314/315 acetylated p65; HAT, histone acetyltransferase; CBP, cAMP-response element-binding protein.

This is an open access article under the CC BY license.

Results

Bcl3 expression is increased in human OC tissues, and promotes survival, proliferation, and migration of OC cells

Expression of miR-125b, which targets Bcl3, is down-regulated in OC tissues (25, 26). However, it is not known whether Bcl3 gene expression is increased in ovarian cancer. To evaluate...
**Bcl3 induces PD-L1 in ovarian cancer cells**

![Diagram A](image1.png)

Figure 1. Bcl3 gene expression is increased in human OC tissues. A, expression of Bcl3 mRNA in normal ovary tissues (column 1) and ovarian serous cystadenocarcinoma (column 2). Data were retrieved from The Cancer Genome Atlas (TCGA) Oncomine data set. B, Bcl3 mRNA levels in normal ovary tissues (column 1), ovarian clear cell adenocarcinoma (column 2), ovarian endometrioid adenocarcinoma (column 3), ovarian mucinous adenocarcinoma (column 4), and ovarian serous adenocarcinoma (column 5). Data were retrieved from the Hendrix Ovarian Statistics (42) dataset. C, Bcl3 expression in normal ovary tissues (column 1) and ovarian serous surface papillary carcinoma tissues (column 2) retrieved from the Welsh dataset (43). D, Bcl3 expression in normal ovary tissues (column 1) and in ovarian carcinoma (column 2) retrieved from the Bonome dataset (44).

To validate the above data, we suppressed and overexpressed Bcl3 in SKOV3 cells using CRISPR knockout and activation plasmids. Suppression of Bcl3 by CRISPR/Cas9 reduced both Bcl3 mRNA (Fig. 4A) and protein levels (Fig. 4, B and C) in SKOV3 and OVCAR3 cells by about 50% compared with control scramble siRNA. Of note, in whole cell extracts (WCE) of OC cells, Bcl3 runs as a doublet of an approximate 50 kDa on SDS gels (Fig. 2B), consistent with previous reports demonstrating Bcl3 phosphorylation (24, 45–47). Importantly, Bcl3 suppression significantly increased apoptosis, evaluated by nucleosome release into the cytoplasm (Fig. 2D) (48) and by caspase-3 assay (Fig. 2E), and decreased proliferation of SKOV3 (Fig. 2F) and OVCAR3 (Fig. 2G) cells. Furthermore, Bcl3 suppression by siRNA significantly reduced migration of OC cells (Fig. 3).

To explore the functional significance of Bcl3 in OC cells, we first examined the effect of Bcl3 suppression on OC cell apoptosis, proliferation, and migration. Suppression of Bcl3 by siRNA decreased Bcl3 mRNA (Fig. 2A) and protein (Fig. 2, B and C) levels in SKOV3 and OVCAR3 cells by about 50% compared with control scramble siRNA. Of note, in whole cell extracts (WCE) of OC cells, Bcl3 runs as a doublet of an approximate 50 kDa on SDS gels (Fig. 2B), consistent with previous reports demonstrating Bcl3 phosphorylation (24, 45–47). Importantly, Bcl3 suppression significantly increased apoptosis, evaluated by nucleosome release into the cytoplasm (Fig. 2D) (48) and by caspase-3 assay (Fig. 2E), and decreased proliferation of SKOV3 (Fig. 2F) and OVCAR3 (Fig. 2G) cells. Furthermore, Bcl3 suppression by siRNA significantly reduced migration of OC cells (Fig. 3).
empty expression vector, SKOV3 cells stably transfected with Bcl3 shRNA express significantly decreased Bcl3 mRNA (Fig. 4A) and protein (Fig. 4, B and C) levels. Importantly, these cells exhibit increased apoptosis (Fig. 4D) and reduced proliferation (Fig. 4G) compared with control SKOV3 cells. These data demonstrate that Bcl3 promotes OC cell survival, migration, and proliferation.

**Bcl3 mediates constitutive PD-L1 expression in OC cells**

Because Bcl3 regulates NF-κB-dependent transcription, we analyzed expression of NF-κB-dependent genes cIAP1, BclxL, TGFβ1, and IkBα in SKOV3 and OVCAR3 cells transfected with Bcl3 siRNA. In addition, because PD-L1 promotes OC growth and cell proliferation (38, 49), and is regulated by NF-κB (30–35), we wondered whether Bcl3 might regulate PD-L1 expression in OC cells. Remarkably, whereas Bcl3 suppression by siRNA did not have a substantial effect on cIAP1, BclxL, TGFβ1, and IkBα mRNA levels, it significantly reduced PD-L1 expression in SKOV3 and OVCAR3 cells (Fig. 5A). In addition, Bcl3 suppression by siRNA significantly decreased the intracellular PD-L1 protein levels in both cell types (Fig. 5, B and C).

To confirm these results, we analyzed PD-L1 expression in SKOV3 cells transfected with Bcl3 CRISPR knockout and activation plasmids. Although Bcl3 suppression by CRISPR knockout did not have a significant effect on cIAP1, BclxL, TGFβ1, and IkBα mRNA levels, it significantly reduced PD-L1 mRNA (Fig. 5D). Conversely, Bcl3 overexpression increased PD-L1 mRNA in SKOV3 cells, but not expression of cIAP1, BclxL, TGFβ1, or IkBα (Fig. 5D). Bcl3 suppression by CRISPR knockout also significantly decreased the intracellular PD-L1 levels, whereas Bcl3 overexpression increased the PD-L1 protein expression in SKOV3 cells (Fig. 5, E and F). Importantly, SKOV3 cells stably transfected with Bcl3 shRNA express significantly reduced PD-L1 protein levels (Fig. 5, E and F). Together, these results indicate that Bcl3 promotes constitutive PD-L1 expression in OC cells.

**IFN induces Bcl3 expression in OC cells**

PD-L1 expression on tumor cells, including OC cells, is induced by IFN produced by CD8 T cells (50–52). Because our
Bcl3 induces PD-L1 in ovarian cancer cells

Bcl3 mediates IFN-induced PD-L1 expression in OC cells

Having shown that Bcl3 promotes the basal PD-L1 expression in OC cells (Fig. 5), and that IFN increases the intracellular levels of Bcl3 and PD-L1 (Fig. 6, A–D), we wanted to determine whether Bcl3 mediates also the IFN-induced PD-L1 expression in OC cells. To this end, we analyzed PD-L1 expression in IFN-treated SKOV3 and OVCAR3 cells transfected with control and Bcl3 siRNA. Bcl3 suppression (Fig. 6E) significantly attenuated the IFN-induced PD-L1 expression in SKOV3 and OVCAR3 cells (Fig. 6F), indicating that Bcl3 mediates the IFN-induced PD-L1 expression in OC cells.

IFN induces PD-L1 promoter occupancy by p65, Lys-314/315 acetylated p65, and p300

Because recent studies have shown that PD-L1 expression is regulated by p65 NF-κB (30–35), we wanted to determine whether the Bcl3-mediated PD-L1 expression in IFN-treated OC cells is associated with an increased p65 promoter occupancy. Furthermore, because Lys-314/315 acetylation of p65 regulates its transcriptional activity in OC cells (53), we analyzed the PD-L1 promoter occupancy by Lys-314/315 ac-p65. The human PD-L1 promoter contains several putative NF-κB-binding sites: κB1 site (GGAAAGTCCA) (30) located at position −65 upstream from the transcription start site (TSS), κB2 site (GGGGGACGCC) (34) located −358 from TSS, κB3 site (GGGAATGCTTCT) located −600 from TSS (30), and κB4/κB5 sites containing an identical putative NF-κB binding sequence (GGGAATTGAC) located −1256 and −1283 from TSS (Fig. 7A). So far, p65 recruitment to the κB2 site has been demonstrated in non-small cell lung cancer and triple negative breast cancer cells (34, 35), and p65 was also recruited to the κB3 site in lipopolysaccharide-stimulated macrophages (30). However, it is not known whether NF-κB binds to the κB1 and/or κB4/κB5 sites, or whether NF-κB occupies the PD-L1 promoter in OC cells.

Thus, we first analyzed using chromatin immunoprecipitation (ChIP) whether p65 and Lys-314/315 ac-p65 are recruited to the PD-L1 κB1, κB2, κB3, and κB4/κB5 sites (Fig. 7A) in IFN-treated SKOV3 cells. Compared with ChIP using control IgG, we detected a statistically significant recruitment of p65 to κB1 (Fig. 7B) and κB2 (Fig. 7C) sites in 6-h IFN-treated cells, even though this occupancy was relatively low. We did not observe any significant recruitment of p65 to κB3 (Fig. 7D) and κB4/κB5 (Fig. 7E) sites. Intriguingly, however, IFN induced a robust recruitment of Lys-314/315 ac-p65, which regulates the specificity of NF-κB-dependent transcription (54, 55), to all κB sites in the PD-L1 promoter (Fig. 7, B–E).

To determine whether the increased PD-L1 promoter occupancy by Lys-314/315 ac-p65 is associated with an increased occupancy of a histone acetyltransferase (HAT), we analyzed recruitment of the HATs cAMP-response element-binding protein (CBP) and p300, known to acetylate p65 (56). Although CBP was not significantly recruited, p300 was heavily recruited to all κB sites in the PD-L1 promoter, and this recruitment was further enhanced by IFN treatment (Fig. 7, B–E). In addition, we tested whether the PD-L1 promoter is occupied by Bcl3;

data showed that Bcl3 promotes PD-L1 expression in OC cells (Fig. 5), we asked whether IFN might regulate the Bcl3 expression. In this regard, Bcl3 expression was reported to be up-regulated by pro-inflammatory cytokines including TNFα, IL-1β, and IL-6 (20). However, to our knowledge, there is no available evidence showing that IFN induces Bcl3 expression. Indeed, human recombinant IFN significantly increased Bcl3 mRNA levels in SKOV3 and OVCAR3 cells (Fig. 6A). In addition, in agreement with a previous study demonstrating increased surface expression of PD-L1 in IFN-treated OC cells (52), IFN significantly increased PD-L1 mRNA levels in both OC cell lines (Fig. 6B). Importantly, IFN also increased intracellular Bcl3 and PD-L1 protein levels in SKOV3 and OVCAR3 cells (Fig. 6, C and D). Together, these data demonstrated that IFN induces Bcl3 expression in OC cells, and suggested a link between IFN, Bcl3, and PD-L1 signaling.

Figure 3. Bcl3 suppression inhibits migration of OC cells. A, SKOV3 cells transfected with control or Bcl3 siRNA were subjected to wound healing assay. Representative photographs at the indicated times from three independent experiments performed in triplicates are shown. Magnification: ×10. B, the wound width was measured in five random fields using ImageJ software by normalizing the average wound width at 24 and 48 h to the average wound width at 0 h. The samples were measured in triplicates and expressed as mean ± S.E.
however, we did not observe any significant recruitment (Fig. 7, B–E).

**Bcl3 and p300 mediate IFN-induced Lys-314/315 ac-p65 recruitment to PD-L1 promoter**

Even though Bcl3 was not directly recruited to the *PD-L1* promoter, we wanted to test whether it might mediate the IFN-induced Lys-314/315 ac-p65, p65, and p300 occupancy. In addition, because p300 was recruited to the *PD-L1* promoter, we analyzed whether it might mediate the IFN-induced Lys-314/315 ac-p65 occupancy. To this end, we measured Lys-314/315 ac-p65, p65, and p300 recruitment to the *PD-L1* promoter in SKOV3 cells transfected with control, Bcl3, and p300 siRNA and treated with IFN (0 and 50 ng/ml) for 6 h. Interestingly, both Bcl3 and p300 silencing significantly suppressed the IFN-induced *PD-L1* promoter occupancy by Lys-314/315 ac-p65 (Fig. 8A). In contrast, p65 recruitment to *PD-L1* promoter was not Bcl3- or p300-dependent (Fig. 8B); however, given the relatively low occupancy of p65 at the *PD-L1* promoter, it was difficult to accurately assess the role of Bcl3 and p300 in p65 recruitment. The occupancy of p300 at the *PD-L1* promoter in both untreated and IFN-treated cells was also not suppressed by Bcl3 silencing (Fig. 8C), indicating that p300 resides on the *PD-L1* promoter even in the absence of Bcl3. Together, these data suggest that the *PD-L1* promoter in OC cells is permanently occupied by p300, and upon IFN stimulation, Bcl3 facilitates Lys-314/315 p65 acetylation and promoter occupancy, resulting in increased *PD-L1* transcription.

**PD-L1 mediates Bcl3 pro-proliferative effect in OC cells**

Because in addition to suppressing the anti-tumor activity of cytotoxic T cells, tumor *PD-L1* has tumor-intrinsic effects (36–38), we asked whether the Bcl3 pro-proliferative effect in OC cells might be mediated by *PD-L1*. To address this question, we analyzed proliferation of SKOV3 and OVCAR3 cells transfected with Bcl3 overexpression or control plasmids, in the presence of *PD-L1* neutralizing antibody, or isotype-matched control IgG. The results demonstrated that compared with
control IgG, PD-L1 neutralizing antibody significantly reduced proliferation of SKOV3 cells, both in cells transfected with control and Bcl3 siRNA. Western blotting of Bcl3, PD-L1, and control actin in WCE from SKOV3 and OVCAR3 cells transfected with control and Bcl3 siRNA. A densitometric evaluation of Bcl3 and PD-L1 protein levels shown in B; Bcl3 and PD-L1 densities were normalized to actin, and expressed as % compared with cells transfected with the control plasmids. D, RT-PCR of NF-κB-dependent genes in SKOV3 cells transfected with control, Bcl3 KO, or Bcl3 ove plasmids. E, Western blotting of Bcl3 and PD-L1 in WCE from SKOV3 cells transfected with control, Bcl3 KO, Bcl3 ove plasmids, or stably transfected with Bcl3 shRNA. F, densitometric evaluation of Bcl3 and PD-L1 protein levels shown in E; Bcl3 and PD-L1 densities were normalized to actin, and expressed as % compared with cells transfected with control plasmids. The values represent the mean ± S.E. of three experiments.

Because IFN increases the Bcl3 expression in OC cells (Fig. 6), and promotes OC tumor growth in mice (52), we tested whether OC cell proliferation in IFN-treated cells also depends on PD-L1. Incubation of SKOV3 (Fig. 9C) and OVCAR3 (Fig. 9D) cells with IFN in the presence of control IgG increased cell proliferation, but this effect was observed only during later incubation times. Importantly, the OC cell proliferation in IFN-treated cells was significantly reduced in the presence of PD-L1 neutralizing antibody. These data are consistent with the recent in vivo study by Abiko et al. (52) demonstrating that the IFN-induced OC tumor growth is PD-L1 dependent. Together, these results indicate that IFN induces Bcl3 expression, resulting in the increased PD-L1 transcription and OC cell proliferation (Fig. 10).

Discussion

Our study shows, rather surprisingly, that in addition to promoting cell survival and proliferation, the proto-oncogene Bcl3 induces expression of PD-L1 in ovarian cancer cells. In addition, our findings demonstrate that Bcl3 expression is increased in OC tissues, and is induced by IFN in OC cells. The mechanism of how Bcl3 induces PD-L1 transcription in IFN-stimulated cells involves an increased, Bcl3- and p300-dependent recruitment of Lys-314/315 ac-p65 to PD-L1 promoter. Because blocking PD-L1 with neutralizing antibody reduces proliferation of OC cells overexpressing Bcl3 or treated with...
IFN, these results suggest that the pro-proliferative effect of Bcl3 in OC cells is partly mediated by PD-L1. Together, these data link Bcl3 to IFN and PD-L1 signaling, and suggest that in addition to mediating cell survival and proliferation, Bcl3 promotes immune escape in cancer cells (Fig. 10).

Bcl-3 was originally identified as a candidate proto-oncogene up-regulated in B-cell chronic lymphocytic leukemia (1, 2); later studies demonstrated its increased expression also in other hematological malignancies, as well as in several types of solid cancer (10–23). The link between Bcl3 overexpression and malignant transformation was suggested to stem from its transcriptional up-regulation of cyclin D1 (57), increased expression of HDM2, the main negative regulator of p53 (58), and regulation of DNA damage response (59). In addition, recent studies have shown that Bcl3 induces expression of pro-inflammatory cytokines IL-8 and IL-17 in cutaneous T cell lymphoma cells (16), and TGFβ signaling in breast cancer (60). Our present findings demonstrate that Bcl3 promotes expression of PD-L1, indicating that in addition to regulating NF-κB-dependent genes involved in cell survival and proliferation, Bcl3 controls genes involved in immune escape. However, the regulation of NF-κB-dependent transcription by Bcl3 is gene specific; whereas Bcl3 induces transcription of PD-L1, it does not have a significant effect on the expression of NF-κB-regulated genes cIAP1, BclxL, TGFβ1, or IκBa, in OC cells (Fig. 5).

Figure 6. IFN induces Bcl3 expression, resulting in increased PD-L1 expression in OC cells. A and B, RT-PCR of Bcl3 (A) and PD-L1 (B) mRNA in SKOV3 and OVCAR3 cells incubated 48 h with increasing IFN. C, Western blotting of Bcl3 and PD-L1 in WCE of SKOV3 and OVCAR3 cells incubated 48 h with IFN. D, densitometric evaluation of Bcl3 and PD-L1 protein levels shown in C; Bcl3 and PD-L1 densities were normalized to actin, and expressed as % compared with untreated (UT) cells. E, Western blotting of Bcl3 in WCE from IFN-treated SKOV3 and OVCAR3 cells transfected with control and Bcl3 siRNA. F, PD-L1 mRNA in IFN-treated SKOV3 and OVCAR3 cells transfected with control and Bcl3 siRNA. The values represent the mean ± S.E. of three experiments.
What determines the specificity of the transcriptional regulation by Bcl3? Because Bcl3 contains a transactivation domain, it can modulate transcription depending on the transcription factors and co-regulators present in the transcription complexes (6–9, 16, 61, 62). In this context, Bcl3 was shown to interact with the NF-κB subunits p50 and p52, the AP-1 transcription factors c-Jun and c-Fos, STAT1, STAT3, PPARγ, class I histone deacetylases, and the HATs CBP and p300 (6–9, 22, 24, 57, 62–66). Our results demonstrate that even though Bcl3 is not directly recruited to the PD-L1 promoter, it mediates, together with the HAT p300 present at the PD-L1 promoter (Fig. 7), the promoter occupancy by Lys-314/315 acetylated p65 NF-κB in IFN-treated OC cells (Fig. 8A). Interestingly, previous studies have reported that acetylation of p65 at Lys-314/315 is mediated by p300, and results in a genespecific regulation of NF-κB-dependent genes in TNF-stimulated cells (54, 55). Together, our data support a model in which the PD-L1 promoter in OC cells is occupied by p300, and upon IFN stimulation, Bcl3 promotes PD-L1 transcription by facilitating the promoter-specific occupancy by Lys-314/315 acetylated p65. Future studies should determine whether IFN induces p65 acetylation on Lys-314/315 by p300, and/or

Figure 7. IFN induces PD-L1 promoter occupancy by p65, Lys-314/315 acetylated p65, and p300 in OC cells. A, schematic illustration of NF-κB–binding sites in human PD-L1 promoter, and ChIP primers used in the ChIP assay. B–E, recruitment of p65, Lys-314/315 ac-p65, CBP, p300, and Bcl3 to PD-L1 κB1 (B), κB2 (C), κB3 (D), and κB4/κB5 sites (E) in IFN (50 ng/ml)–treated SKOV3 cells was analyzed by ChIP and quantified by real-time PCR; ChIP using control IgG is also shown. Each condition (antibody used at each time point) represents ~1.25 × 10⁴ cells. The data are presented as fold-difference in occupancy of the particular protein at the particular locus compared with the human IGX1A (SA Biosciences) locus, and represent the mean ± S.E. of three experiments. Asterisks denote a statistically significant (*, p < 0.05; **, p < 0.01; ***, p < 0.001) change compared with ChIP using control IgG at the corresponding time.
whether it induces histone deacetylases’s removal. In addition, it will be interesting to determine whether the high promoter occupancy by Lys-314/315 ac-p65 in IFN-treated OC cells is unique for PD-L1, or whether IFN induces Lys-314/315 ac-p65 recruitment to other NF-κB-dependent promoters as well.

Little is known about the signaling pathways inducing Bcl3 expression in cancer cells. In line with the reported induction of Bcl3 by p65 NF-κB (68), Bcl3 expression was shown to be up-regulated by pro-inflammatory cytokines including TNFα, IL-1, and IL-6 (20). Our study is the first to demonstrate that the Bcl3 expression is induced also by IFNγ (Fig. 6). The induction of Bcl3 by IFN is intriguing, especially because our data also show that the IFN-induced Bcl3 expression promotes expression of PD-L1 in IFN-stimulated cells (Fig. 6), thus linking Bcl3 to IFN and PD-L1 signaling.

Increased PD-L1 expression in OC tissues promotes tumor growth (39–41), but the regulation of PD-L1 expression in OC cells is little understood. Our study demonstrates that the PD-L1 expression in OC cells is regulated by the proto-oncogene Bcl3. Analysis of four different public datasets, together containing 26 control ovarian tissues and 898 OC samples, has revealed that the Bcl3 gene expression is statistically increased in OC tissues (p < 0.016; Fig. 1). Interestingly, the Bcl3 expression was most significantly increased in ovarian serous surface papillary carcinoma (Fig. 1C) (43). Even though the sample size was relatively small, these data suggest that this type of OC has a significantly higher Bcl3 expression compared with other
types of OC. Alternatively, as the tumor samples are often heterogeneous, a subset of cancer cells may express higher levels of Bcl3. It will be important to correlate these data in future with Bcl3 protein levels in individual cells. In addition, because the Bcl3 transcriptional activity is regulated by phosphorylation (24, 45–47), future studies should analyze the phosphorylation status of nuclear Bcl3 in OC tissues.

In addition to inhibiting anti-tumor cytotoxic T cells, the tumor-expressed PD-L1 has tumor-intrinsic effects that include the regulation of cancer cell survival and proliferation, autophagy, and regulation of glucose metabolism and mTOR signaling (36–38). Our results show that Bcl3 has prosurvival and pro-proliferative effects in OC cells (Figs. 2–4). However, because blocking the Bcl3-induced PD-L1 by neutralizing antibody decreases proliferation in Bcl3-overexpressing cells (Fig. 9), these data indicate that the Bcl3 prosurvival effect in OC cells is, at least partly, mediated by the Bcl3-up-regulated PD-L1. In summary, our study identifies PD-L1 as a novel target of Bcl3, indicating that Bcl3 regulates not only cancer cell proliferation and survival, but also immune escape.

**Experimental procedures**

**Cell culture**

Human ovarian cancer SKOV3 and OVCAR3 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD). Cells were cultured (5 × 10^5 cells/ml) in 6-well plates in RPMI 1640 medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen) and antibiotics at 37 °C with 5% CO2 as described (53). For treatment with IFNγ, human recombinant IFNγ (285-IF-100; R&D Systems, Minneapolis, MN) was reconstituted in sterile water. Cell viability was measured by trypan blue exclusion.

**Transfection with siRNA and CRISPR knockout and overexpression plasmids**

Human Bcl3 (sc-29789) and nonsilencing (sc-37007) siRNAs were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Prior to transfection, 2 × 10^5 cells were seeded into a 6-well plate and incubated in a humidified 5% CO2 atmosphere at 37 °C in antibiotic-free RPMI medium supplement with 10%
FBS for 24 h to about 80% confluence. For each transfection, 80 pmol of either nonsilencing siRNA control or Bcl3 siRNA were used. Cells were transfected 7 h in transfection medium with siRNA transfection reagent according to the manufacturer's instructions (Santa Cruz Biotechnology). After transfection, fresh medium with antibiotics was added, and cells were grown for 24 h before treatment.

Bcl3 CRISPR/Cas9 knockout (KO) plasmid (sc-400740), control CRISPR/Cas9 plasmid (sc-418922), Bcl-3 CRISPR activation plasmid (sc-400740-ACD), and control CRISPR activation plasmid (sc-437275) were obtained from Santa Cruz Biotechnology. Prior to transfections, 2 × 10^5 cells were seeded into a 6-well plate and incubated in antibiotic-free RPMI medium supplement with 10% FBS for 24 h to 80% confluence. For each transfection, 3 μg of Bcl3 CRISPR/Cas9 KO or activation plasmids, or the corresponding control plasmids were used. Cells were transfected 24 h in plasmid transfection medium according to the manufacturer's instructions (Santa Cruz Biotechnology). After transfection, fresh medium with antibiotics was added, and cells were grown for 24 h before treatment.

For stable transfection, Bcl3 shRNA (sc-29789-SH) and control shRNA (sc-108060) plasmids were obtained from Santa Cruz Biotechnology. For each transfection, 2 μg of Bcl3 shRNA or control shRNA plasmid were used, and cells were transfected using shRNA plasmid transfection medium (sc-108062) and transfection reagent (sc-108061) according to the manufacturer's instructions (Santa Cruz Biotechnology). Transfected colonies were selected using 3 μg/ml of puromycin.

Apoptosis, cell proliferation, and PD-L1 neutralization assays

Apoptosis was evaluated using a cell death detection ELISA kit that quantifies release of nucleosomes into the cytoplasm (Cell Death Detection ELISAPLUS; Roche Applied Science) (48), and by measuring caspase 3 activity using a human active caspase 3 ELISA kit (ab181418, Abcam, Cambridge, MA).

Cell proliferation was measured by CellTiter 96 One Solution Cell Proliferation Assay (Promega, Madison, WI). Transfected cells were seeded into 96-well plates at a density of 5000 cells/100 μl of medium, and incubated at 37 °C. At the indicated time points, 20 μl of CellTiter 96 One Solution Reagent was added to each well, incubated for 4 h at 37 °C, and absorbance at 490 nm was measured.

For PD-L1 neutralization experiments, transfected cells were incubated in the presence of 500 nM anti-PD-L1 (CD274) neutralizing IgG1κ antibody (catalog 71213; BPS Bioscience, San Diego, CA) or isotype control IgG1κ antibody (catalog 14-4714-82; Thermo Fisher Scientific), and cell proliferation was measured as described above.

Wound healing assay

SKOV3 cells were seeded in 6-well plates (2 × 10^5 cells/well) and transfected with control or Bcl3 siRNA as described above. Once the cells became confluent, a wound area was created by scraping the cell monolayer with a sterile 200-μl pipette tip. After washing twice with PBS, RPMI medium without FBS was added to the wells. The scratch area was monitored under a phase-contrast microscope at 0, 24, and 48 h after transfection. The wound width was measured in five random fields using ImageJ software. All samples were tested in triplicates.

Real-time RT-PCR

Total RNA was isolated using RNeasy mini-kit (Qiagen, Valencia, CA). The iScript one-step RT-PCR kit with SYBR Green (Bio-Rad) was used as a Supermix and 20 ng/μl of RNA was used as template on a Bio-Rad MyIQ Single Color Real-Time PCR Detection System (Bio-Rad). The primers used for quantification of human Bcl3, PD-L1, cIAP1, BclxL, TGFβ1, IκBα, p65, and actin mRNA were purchased from SA Biosciences (Frederick, MD). The mRNA values are expressed as a percentage of control or untreated samples, which were arbitrarily set as 100%.

Western blot analysis

WCE were prepared as described previously (48, 53). Denatured proteins were separated on 12% denaturing polyacrylamide gels and transferred to nitrocellulose membrane (Hybond C; Amersham Biosciences). Membranes were blocked with a 5% (w/v) nonfat dried milk solution containing 10 mM Tris-Cl, pH 7.5, 140 mM NaCl, 1.5 mM MgCl2, and 0.1% Tween 20 (TBSTM), and incubated with Bcl3 (23959–1-AP; Proteintech, Rosemont, IL) or PD-L1 (E1L3N; Cell Signaling, Danvers, MA) antibodies diluted in 20 (TBSTM), and incubated with Bcl3 (23959–1-AP; Proteintech, Rosemont, IL) or PD-L1 (E1L3N; Cell Signaling, Danvers, MA) antibodies diluted in TBSTM. After washing, the membranes were incubated with horseradish peroxidase-labeled secondary antibodies and the labeled proteins were detected using the ECL detection system (Amersham Biosciences). To confirm equivalent amounts of loaded proteins, the membranes were stripped and re-probed with control anti-actin antibody as described (48, 53).

Chromatin immunoprecipitation (ChIP)

ChIP analysis was performed as described (67). Briefly, proteins and DNA were cross-linked by formaldehyde, and cells

![Figure 10. Proposed model of IFN-induced Bcl3 expression, resulting in increased PD-L1 promoter occupancy by Lys-314/315 ac-p65, and increased PD-L1 expression and proliferation in OC cells. Findings from this study are indicated by red arrows.](Image)
Bcl3 induces PD-L1 in ovarian cancer cells

were washed and sonicated. The lysates were centrifuged (15,000 × g, 10 min, 4 °C), and the supernatant extracts were diluted with ChIP dilution buffer and pre-cleared with Protein A/G-agarose (Santa Cruz Biotechnology) for 2 h at 4 °C. Immunoprecipitations were performed overnight at 4°C, using p65 (MAB3026; Sigma), Lys-314/315 acetylated p65 (HW136; Signalway Antibody, College Park, MD), CBP (sc-7300; Santa Cruz Biotechnology), p300 (sc-585; Santa Cruz Biotechnology), CBP (sc-7300; Santa Cruz Biotechnology), p300 (sc-585; Santa Cruz Biotechnology), Bcl3 (23959–1-AP; Proteintech), and control IgG (sc-2025) antibodies that were pre-incubated (6 h, 4 °C) with Protein A/G-agarose, and the immune complexes were collected by centrifugation (150 × g, 5 min, 4 °C), washed, and extracted with 1% SDS, 0.1 M NaHCO3. After reversing the cross-linking, proteins were digested with proteinase K, and the samples were extracted with phenol/chloroform, followed by precipitation with ethanol. Immunoprecipitated DNA was analyzed by real-time PCR (25 µl reaction mixture) using the iQ SYBR Green Supermix and the Bio-Rad MyiQ Single Color Real-Time PCR Detection System (Bio-Rad). Each immunoprecipitation was performed at least three times using different chromatin samples, and the occupancy was calculated by using the human IGX1A negative control primers (SA Biosciences, Frederick, MD), which detect specific genomic ORF-free DNA sequence that does not contain a binding site for any known transcription factors. The results were calculated as fold-difference in occupancy of the particular protein at the particular locus compared with the IGX1A locus.

The PD-L1 primers used for real-time PCR were as follows: PD-L1-forward, 5'-CTTTATCTTCTAAGCACTACACT-3' and reverse, 5'-CAAGCCGACAAATCCAGGT-3'; PD-L1-forward, 5'-TGAGGTCCTGTCTGAATTCTTT-3' and reverse, 5'-AGAGGGTAAAGACGTAAAGGT-3'; PD-L1-forward, 5'-CTCGAGGCCTTAATCCT-3' and reverse, 5'-ACTCTCTCAAAGTCTCCGACAC-3'; PD-L1-forward, 5'-TGGCACATAATGTCTATA-3' and reverse, 5'-CCAGCTCAGATGTTCCTCT-3'.

Statistical analysis

The results represent at least three independent experiments. Numerical results are presented as mean ± S.E. Data were analyzed by using InStat software package (GraphPad, San Diego, CA). Statistical significance was evaluated by using Mann-Whitney U test, and p < 0.05 was considered significant. Levels of significance are indicated as *, p < 0.05; **, p < 0.01; and †††, p < 0.001.

Author contributions—Y. Zou and I. V. data curation; Y. Zou and I. V. formal analysis; Y. Zou and I. V. validation; Y. Zou, M. M. U., S. P., Y. Zhu, A. V., and I. V. investigation; Y. Zou and I. V. visualization; Y. Zou, M. M. U., S. P., Y. Zhu, P. B., A. V., and I. V. methodology; Y. Zou, M. M. U., S. P., Y. Zhu, P. B., A. V., and I. V. writing-review and editing; Y. Zhu, A. V., and I. V. resources; I. V. conceptualization; I. V. supervision; I. V. funding acquisition; I. V. writing-original draft; I. V. project administration.
18. Thornburg, N. J., Pathmanathan, R., and Raab-Traub, N. (2003) Activation of NFκB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 63, 8293–8301 Medline

19. Puvvada, S. D., Funkhouser, W. K., Greene, K., Deal, A., Chu, H., Baldwin, A. S., Tepper, J. E., and O’Neil, B. H. (2010) NF-κB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology 78, 181–188 CrossRef Medline

20. Maldonado, V., and Melendez-Zaigla, J. (2011) Role of Bcl-3 in solid tumors. Mol. Cancer 10, 152 CrossRef Medline

21. Wakefield, A., Soukupova, J., Ranger, J., French, R., Muller, W. J., and Clarkson, R. W. (2013) Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. Cancer Res. 73, 745–755 CrossRef Medline

22. Wu, J., Li, L., Jiang, G., Zhan, H., and Wang, N. (2016) B-cell CLL/lymphoma 3 promotes glioma cell proliferation and inhibits apoptosis through the oncogenic STAT3 pathway. Int. J. Oncol. 49, 2471–2479 CrossRef Medline

23. Zhao, H., Wang, W., Zhao, Q., Hu, G., Deng, K., and Liu, Y. (2016) Bcl3 exerts an oncogenic function by regulating STAT3 in human cervical cancer. Oncotarget 7, 6619–6629 CrossRef Medline

24. Viatour, P., Dejardin, E., Warner, M., Lai, F., Claudio, E., Bureau, F., Marine, J. C., Merville, M. P., Maurer, U., Green, D., Pariet, J., Siebenlist, U., Bours, V., and Chariot, A. (2004) GSK3-mediated BCL-3 phosphorylation modulates its degradation and oncogenicity. Mol. Cell 16, 33–45 CrossRef Medline

25. Guan, Y., Yao, H., Zheng, Z., Qiu, G., and Sun, K. (2011) MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int. J. Cancer 128, 2274–2283 CrossRef Medline

26. Luo, S., Wang, J., Ma, Y., Yao, Z., and Pan, H. (2015) PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-125b. Biochem. Biophys. Res. Commun. 462, 85–90 CrossRef Medline

27. Huang, S., Robinson, B. J., Deguzman, A., Buca, C. D., and Fitzjarrell, I. L. (2000) Blockade of NFκB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60, 5334–5339 Medline

28. Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Saito, M., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., Sakata, M., Motoyaama, T., Kurachi, H., Tatsuki, K., and Murata, Y. (2004) Inhibition of NFκB increases the efficacy of cisplatin in vitro and in vivo ovarian cancer models. J. Biol. Chem. 279, 23477–23485 CrossRef Medline

29. Annunziata, C. M., Stavnes, H. T., Kleinberg, L., Berner, A., Hernandez, L. F., Birrer, M. J., Steinberg, S. M., Davidson, B., and Kohn, E. C. (2010) Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer 116, 3276–3284 CrossRef Medline

30. Huang, G., Wen, Q., Zhao, Y., Gao, Q., and Bai, Y. (2013) NF-κB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS ONE 8, e61602 CrossRef Medline

31. Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., Honjo, T., and Fuji, S. (2007) Programmed cell death ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA. 104, 3360–3365 CrossRef Medline

32. Abiko, K., Mandai, M., Hamanishi, J., Yoshioka, Y., Matsumura, N., Baba, T., Yamaguchi, K., Murakami, R., Yamamoto, A., Kharma, B., Kosaka, K., and Konishi, I. (2013) PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin. Cancer Res. 19, 1363–1374 CrossRef Medline

33. Maine, C. J., Aziz, N. H., Chatterjee, J., Hayford, C., Brewig, N., Whilding, L., George, A. J., and Ghaim-Maghami, S. (2014) Programmed death ligand-1 overexpression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol. Immunother. 63, 215–224 CrossRef Medline

34. Hendrix, N. D., Wu, R., Kuck, R., Schwartz, D. R., Fearon, E. R., and Cho, K. R. (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 66, 1354–1362 CrossRef Medline

35. Walsh, J. B., Zarrinkar, P. P., Sapinoso, L. M., Kerr, S. G., Behling, C. A., Monk, B. J., Lockhart, D. J., Sugar, R. A., and Hampton, G. M. (2001) Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA. 98, 1176–1181 CrossRef Medline

36. Bonome, T., Levine, D. A., Shih, J., Randonovich, M., Pise-Masison, C. A., Bogomolniy, F., Ozubon, L., Brady, J., Barrett, J. C., Boyd, J., and Birrer, M. J. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 68, 5478–5486 CrossRef Medline

37. Bundy, D. L., and McKeithan, T. W. (1997) Diverse effects of BCL3 phosphorylation on its modulation of NFκB p52 homodimer binding to DNA. J. Biol. Chem. 272, 33132–33139 Medline

38. Nishikori, M., Ohno, H., Haga, H., and Uchiyama, T. (2005) Stimulation of CD30 in anaplastic large cell lymphoma leads to production of NFκB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci. 96, 487–497 CrossRef Medline

39. Wang, Y. Y., Li, Y., Kim, D., Zhong, X., Du, Q., Ghassemian, M., and Ghosh, G. (2017) Bcl3 phosphorylation by Akt, Erk2, and IKK is required for its transcriptional activity. Mol. Cell 67, 484–497 CrossRef Medline

40. Juvekar, A., Manna, S., Ramaswami, S., Chang, T. P., Yu, H. Y., Ghosh, C. C., Celiker, M. Y., and Vancurova, I. (2011) Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NFκB expression by NFκB-dependent transcription and induction of apoptosis in CTCL. Mol. Cancer Res. 9, 183–194 CrossRef Medline

41. Duraiswamy, J., Freeman, G. J., and Coukos, G. (2013) Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73, 6900–6912 CrossRef Medline

42. Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., Horton, H. F.,
**Bcl3 induces PD-L1 in ovarian cancer cells**

Fouser, L., Carter, L., Ling, V., Bowman, M. R., et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J. Exp. Med.* **192**, 1027–1034 CrossRef Medline

Blank, C., Brown, L., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., and Gajewski, T. F. (2004) PD-L1/B7-H1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. *Cancer Res.* **64**, 1140–1145 CrossRef Medline

Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., and Mandai, M. (2015) IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. *Br. J. Cancer* **112**, 1501–1509 CrossRef Medline

Gatla, H. R., Zou, Y., Uddin, M. M., Singha, B., Bu, P., Vancura, A., and Vancurova, I. (2017) Histone deacetylase (HDAC) inhibition induces IκB kinase (IKK)-dependent interleukin-8/CXCL8 expression in ovarian cancer cells. *J. Biol. Chem.* **292**, 5043–5054 CrossRef Medline

Buerki, C., Rothgiesser, K. M., Valovka, T., Owen, H. R., Rehrauer, H., Fey, M., Lane, W. S., and Hottiger, M. O. (2008) Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. *Nucleic Acids Res.* **36**, 1665–1680 CrossRef Medline

Rothgiesser, K. M., Fey, M., and Hottiger, M. O. (2010) Acetylation of p65 at lysine 314 is important for late NFκB-dependent gene expression. *BMC Genomics* **11**, 22 CrossRef

Vancurova, I., Uddin, M. M., Zou, Y., and Vancura, A. (2018) Combination therapies targeting HDAC and IKK in solid tumors. *Trends Pharmacol. Sci.* **39**, 295–306 CrossRef Medline

Westerheide, S. D., Mayo, M. W., Anest, V., Hanson, J. L., and Baldwin, A. S., Jr. (2001) The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G1 transition. *Mol. Cell Biol.* **21**, 8428–8436 CrossRef Medline

Kashatus, D., Cogswell, P., and Baldwin, A. S. (2006) Expression of the Bcl-3 proto-oncogene suppresses p53 activation. *Genes Dev.* **20**, 225–235 CrossRef Medline

Zamora, R., Espinosa, M., Ceballos-Cancino, G., Segura, B., Maldonado, V., and Melendez-Zaglao, J. (2010) Depletion of the oncprotein Bcl-3 induces centrosome amplification and aneuploidy in cancer cells. *Mol. Cancer* **9**, 223 CrossRef

Chen, X., Cao, C., Sun, X., Lei, R., Chen, P., Zhao, Y., Jiang, Y., Yin, J., Chen, R., Ye, D., Wang, Q., Liu, Z., Liu, S., Cheng, C., Mao, J., et al. (2016) Bcl3 regulates TGFβ signaling by stabilizing Smad3 during breast cancer pulmonary metastasis. *Cell Death Dis.* **7**, e2508 CrossRef

Wang, V. Y., Huang, W., Asagiri, M., Spann, N., Hoffmann, A., Glass, C., and Ghosh, G. (2012) The transcriptional specificity of NF-κB dimers is coded within the κB DNA response elements. *Cell Rep.* **2**, 824–839 CrossRef Medline

Carmony, R. J., Ruan, Q., Palmer, S., Hillard, B., and Chen, Y. H. (2007) Negative regulation of Toll-like receptor signaling by NFκB p50 ubiquitination blockade. *Science* **317**, 675–678 CrossRef Medline

Na, S. Y., Choi, J. E., Kim, H. J., Jhun, B. H., Lee, Y. C., and Lee, J. W. (1999) Bcl3, an IκB protein, stimulates activating protein-1 transactivation and cellular proliferation. *J. Biol. Chem.* **274**, 28491–28496 CrossRef Medline

Dechend, R., Hirano, F., Lehmann, K., Heissmeyer, V., Ansieau, S., Wulczyn, F. G., Scheidereit, C., and Leutz, A. (1999) The Bcl-3 oncprotein acts as a bridging factor between NFκB/Rel and nuclear co-regulators. *Onco. gene* **18**, 3316–3323 CrossRef Medline

Kim, Y. M., Sharma, N., and Nyborg, J. K. (2008) The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter. *J. Virol.* **82**, 11939–11947 CrossRef Medline

Yang, J., Williams, R. S., and Kelly, D. P. (2009) Bcl3 interacts cooperatively with peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1α to coactivate nuclear receptors estrogen-related receptor alpha and PPARα. *Mol. Cell Biol.* **29**, 4091–4102 CrossRef Medline

Chang, T. P., Kim, M., and Vancurova, I. (2016) Analysis of TGFβ1 and IL-10 transcriptional regulation in CTCL cells by chromatin immunoprecipitation. *Methods Mol. Biol.* **1172**, 329–341 CrossRef Medline

Brasier, A. R., Lu, M., Hai, T., Lu, Y., and Boldogh, I. (2001) NFκB-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NFκB1 residence. *J. Biol. Chem.* **276**, 32080–32093 CrossRef Medline